News Snapshot:
BioNTech vaccinations have restarted in Hong Kong following a 12-day suspension over packaging defects, putting the city’s Covid-19 inoculation drive back on track for the widespread protection of its population and the ultimate goal of herd immunity. The development returns the Hong Kong campaign to a two-vaccine approach, with doses from Chinese company Sinovac also being administered to the public. While both versions were accepted for emergency use in Hong Kong, BioNTech’s jab has also secured approval from the World Health Organization (WHO), which is expected to do the same for the Sinovac one by the end of April. Coronavirus:...
